Scott Allen Conner

US Patent:

6982278, Jan 3, 2006

Filed:

Aug 23, 2001

Appl. No.:

10/343474

Inventors:

Dawn Alisa Brooks - Indianapolis IN, US
Scott Eugene Conner - Elizabethtown IN, US
Samuel James Dominianni - Indianapolis IN, US
Alexander Glenn Godfrey - Mooresville IN, US
Lynn Stacy Gossett - Indianapolis IN, US
Christopher John Rit - Martinsville IN, US
Allie Edward Tripp - Indianapolis IN, US
Alan M. Warshawsky - Carmel IN, US
Guoxin Zhu - Noblesville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/421
C07D 263/30

US Classification:

514374, 548215, 548236

Abstract:

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

US Patent:

7351728, Apr 1, 2008

Filed:

Jul 14, 2005

Appl. No.:

11/181640

Inventors:

Dawn Alisa Brooks - Indianapolis IN, US
Scott Eugene Conner - Elizabethtown IN, US
Samuel James Dominianni - Indianapolis IN, US
Alexander Glenn Godfrey - Mooresville IN, US
Lynn Stacy Gossett - Indianapolis IN, US
Christopher John Rito - Martinsville IN, US
Allie Edward Tripp - Indianapolis IN, US
Alan M. Warshawsky - Carmel IN, US
Guoxin Zhu - Noblesville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/421
C07D 263/32

US Classification:

514374, 548215, 548235, 548236

Abstract:

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

US Patent:

7384965, Jun 10, 2008

Filed:

Dec 31, 2003

Appl. No.:

10/539477

Inventors:

Scott Eugene Conner - Indianapolis IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Guoxin Zhu - Noblesville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/428
A61K 31/426
A61K 31/421
A61K 31/423
C07D 277/66
C07D 263/57

US Classification:

514367, 514375, 548179, 548224, 548152, 548217

Abstract:

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S, S(O)and N; (b) U ia an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4) A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C-Calkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

US Patent:

7396850, Jul 8, 2008

Filed:

Dec 31, 2003

Appl. No.:

10/537282

Inventors:

Scott Eugene Conner - Indianapolis IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Daniel Ray Mayhugh - Carmel IN, US
Guoxin Zhu - Noblesville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/415
C07D 231/10

US Classification:

514406, 5483561, 5483731, 5483761, 514403, 424 137

Abstract:

The present invention is directed to a compound, {2-Methyl-4-[3-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid and pharmaceutical uses thereof.

US Patent:

7405305, Jul 29, 2008

Filed:

Mar 5, 2003

Appl. No.:

10/506029

Inventors:

Pamela Ann Albaugh - Carlsbad CA, US
Jochen Ammenn - Hamburg, DE
Timothy Paul Burkholder - Carmel IN, US
Joshua Ryan Clayton - Cicero IN, US
Scott Eugene Conner - Indianapolis IN, US
Brian Eugene Cunningham - Martinsville IN, US
Thomas Albert Engler - Indianapolis IN, US
Kelly Wayne Furness - Avon IN, US
James Robert Henry - Indianapolis IN, US
Sushant Malhotra - Indianapolis IN, US
Mark Joseph Tebbe - Indianapolis IN, US
Guoxin Zhu - Noblesville IN, US
YiHong Li - Carmel IN, US
Brian Raymond Berridge - Greenfield IN, US
Charles Edward Ruegg - Indianapolis IN, US
John Morris Sullivan - Greenfield IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D 209/12
C07D 207/24
C07D 211/06

US Classification:

548469, 548547, 546184

Abstract:

The present invention provides kinase inhibitors of Formula (I).

US Patent:

7528160, May 5, 2009

Filed:

Dec 31, 2003

Appl. No.:

10/541502

Inventors:

Scott Eugene Conner - Indianapolis IN, US
James Allen Knobelsdorf - Fishers IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Daniel Ray Mayhugh - Carmel IN, US
Xiaodong Wang - Carmel IN, US
Guoxin Zhu - Indianapolis IN, US
Jeffrey Michael Schkeryantz - Fishers IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/427
C07D 277/24

US Classification:

514365, 548203

Abstract:

The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

US Patent:

7598266, Oct 6, 2009

Filed:

Apr 9, 2008

Appl. No.:

12/099929

Inventors:

Scott Eugene Conner - Indianapolis IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Guoxin Zhu - Noblesville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/437
A61K 31/4353
C07D 471/04

US Classification:

514303, 514300, 546118, 546113

Abstract:

The present invention is directed to compounds represented by the following structural formula, Formula I:.

US Patent:

7655641, Feb 2, 2010

Filed:

Feb 10, 2004

Appl. No.:

10/542579

Inventors:

Scott Eugene Conner - Indianapolis IN, US
Lynn Stacy Gossett - Indianapolis IN, US
Jonathan Edward Green - Avon IN, US
Nathan Bryan Mantlo - Brownsburg IN, US
Donald Paul Matthews - Indianapolis IN, US
Daniel Ray Mayhugh - Carmel IN, US
Daryl Lynn Smith - Fishers IN, US
Jennifer Ann Vance - San Jose CA, US
Xiaodong Wang - Carmel IN, US
Alan M Warshawsky - Carmel IN, US
Yanping Xu - Fishers IN, US
Guoxin Zhu - Noblesville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/66
A61K 31/38
C07D 409/12
C07D 209/04

US Classification:

514141, 514443, 548467, 549 51, 549 52, 549 54, 549 55

Abstract:

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.